Evidence map›Paper›PMID 39091730›Full record

ArticlebioRxiv : the preprint server for biology2024

Computationally designed mRNA-launched protein nanoparticle vaccines.

Grace G Hendricks, Lilit Grigoryan, Mary Jane Navarro, Nicholas J Catanzaro, Miranda L Hubbard, John M Powers, Melissa Mattocks, Catherine Treichel, Alexandra C Walls, Jimin Lee and 23 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

33 authors.

Grace G HendricksInstitute for Protein Design, University of Washington, Seattle, WA, USA.ORCID 0009-0008-5844-1403
Lilit GrigoryanInstitute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford University, Stanford, CA, USA.
Mary Jane NavarroDepartment of Biochemistry, University of Washington, Seattle, WA, USA.
Nicholas J CatanzaroDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Miranda L HubbardDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
John M PowersDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Melissa MattocksDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Catherine TreichelInstitute for Protein Design, University of Washington, Seattle, WA, USA.
Alexandra C WallsDepartment of Biochemistry, University of Washington, Seattle, WA, USA.
Jimin LeeDepartment of Biochemistry, University of Washington, Seattle, WA, USA.
Daniel EllisInstitute for Protein Design, University of Washington, Seattle, WA, USA.
Jing Yang John WangInstitute for Protein Design, University of Washington, Seattle, WA, USA.
Suna ChengInstitute for Protein Design, University of Washington, Seattle, WA, USA.
Marcos C MirandaInstitute for Protein Design, University of Washington, Seattle, WA, USA.
Adian ValdezInstitute for Protein Design, University of Washington, Seattle, WA, USA.
Cara W ChaoInstitute for Protein Design, University of Washington, Seattle, WA, USA.
Sidney ChanInstitute for Protein Design, University of Washington, Seattle, WA, USA.
Christine MenInstitute for Protein Design, University of Washington, Seattle, WA, USA.
Max R JohnsonInstitute for Protein Design, University of Washington, Seattle, WA, USA.
Harold HuiInstitute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford University, Stanford, CA, USA.
Sheng-Yang WuInstitute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford University, Stanford, CA, USA.
Victor LujanInstitute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford University, Stanford, CA, USA.
Hiromi MuramatsuDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Paulo J C LinAcuitas Therapeutics, Vancouver, BC, Canada.
Molly M H SungAcuitas Therapeutics, Vancouver, BC, Canada.
Ying K TamAcuitas Therapeutics, Vancouver, BC, Canada.
Elizabeth M LeafInstitute for Protein Design, University of Washington, Seattle, WA, USA.
Norbert PardiDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Ralph S BaricDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Bali PulendranInstitute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford University, Stanford, CA, USA.
David VeeslerDepartment of Biochemistry, University of Washington, Seattle, WA, USA.
Alexandra SchäferDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Neil P KingInstitute for Protein Design, University of Washington, Seattle, WA, USA.

Funding

Project 4: Computational panbetaCoV immunogen designP01AI158571 · NIAID · DUKE UNIVERSITY · PI HAYNES, BARTON F. · 2021 to 2023
$28.0M
Centers for Research on Structural Biology of Infectious Diseases: Universal Influenza Vaccine Research75N93022C00036 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI STAKER, BART · 2022 to 2025
$21.7M
Structure-based design of broadly protective coronavirus vaccinesP01AI167966 · NIAID · UNIVERSITY OF WASHINGTON · PI Ralph S Baric · 2022 to 2026
$15.3M
Understanding antibody responses and defining correlates of protection for endemic and pandemic coronavirus strainsP01AI172531 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Florian Krammer · 2023 to 2026
$12.5M
Unraveling the bat humoral immune response against zoonotic viruses to guide the design of next-generation therapeuticsDP1AI158186 · NIAID · UNIVERSITY OF WASHINGTON · PI VEESLER, DAVID · 2020 to 2024
$5.4M
Lipid nanoparticles as novel adjuvants inducing effective T follicular helper cell and humoral immune responsesR01AI153064 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Michela Locci, Norbert Pardi · 2020 to 2026
$4.2M
NIAID NIH HHS 75N93022C00036NIAID NIH HHS DP1 AI158186NIAID NIH HHS P01 AI158571NIAID NIH HHS P01 AI167966NIAID NIH HHS P01 AI172531NIAID NIH HHS R01 AI153064
6 · The paper itself

Abstract

Both protein nanoparticle and mRNA vaccines were clinically de-risked during the COVID-19 pandemic

Identifiers

PMID39091730
PMCPMC11291046

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.